GlobeNewswire Inc | Nov 2, 2020 06:45AM EST

November 02, 2020

BERWYN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimers disease (AD), Parkinsons disease (PD) and other neurodegenerative diseases, today announced its Founder and CEO, Maria Maccecchini, Ph.D., is presenting at the Meridian Clinical Trials Summit on November 2, 2020 at 10 a.m. ET.

Dr. Maccecchinis presentation, De-risking Phase 3 clinical studies in Phase 2; case study from Alzheimers and Parkinsons, will share insight learned from the Companys ongoing clinical studies which are measuring all the steps in the toxic cascade leading to nerve cell death and how ANVS401, the Companys lead compound, might reverse the toxic cascade and recover normal brain function.

I look forward to sharing with the attendees how I believe we are effectively de-risking our clinical trial programs through our current Phase 2a studies, commented, Dr. Maccecchini.

About Annovis Bio

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimers disease (AD), Parkinsons disease (PD) and Alzheimers in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have an ongoing Phase 2a study in AD patients and have commenced a second Phase 2a study in AD and PD patients. For more information on Annovis, please visit the companys website:www.annovisbio.com.

Forward-Looking Statements

Statements in this press release contain forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as anticipate, expect, believe, will, may, should, estimate, project, outlook, forecast or other similar words, and include, without limitation, statements regarding the timing, effectiveness and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including that clinical trials may be delayed. These and other risks and uncertainties are described more fully in the section titled Risk Factors in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

Investor Relations:

Dave Gentry, CEORedChip Companies Inc.407-491-4498Dave@redchip.com

SOURCE: Annovis Bio, Inc.